Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004887231 | Stomach | CAG | homeostasis of number of cells | 17/552 | 272/18723 | 3.05e-03 | 3.01e-02 | 17 |
GO:003133331 | Stomach | CAG | negative regulation of protein-containing complex assembly | 11/552 | 141/18723 | 3.09e-03 | 3.04e-02 | 11 |
GO:0050921 | Stomach | CAG | positive regulation of chemotaxis | 11/552 | 141/18723 | 3.09e-03 | 3.04e-02 | 11 |
GO:00329441 | Stomach | CAG | regulation of mononuclear cell proliferation | 15/552 | 227/18723 | 3.11e-03 | 3.05e-02 | 15 |
GO:000989631 | Stomach | CAG | positive regulation of catabolic process | 26/552 | 492/18723 | 3.14e-03 | 3.08e-02 | 26 |
GO:00327603 | Stomach | CAG | positive regulation of tumor necrosis factor production | 9/552 | 103/18723 | 3.40e-03 | 3.26e-02 | 9 |
GO:00456393 | Stomach | CAG | positive regulation of myeloid cell differentiation | 9/552 | 103/18723 | 3.40e-03 | 3.26e-02 | 9 |
GO:00506792 | Stomach | CAG | positive regulation of epithelial cell proliferation | 14/552 | 207/18723 | 3.42e-03 | 3.27e-02 | 14 |
GO:00320694 | Stomach | CAG | regulation of nuclease activity | 4/552 | 22/18723 | 3.58e-03 | 3.34e-02 | 4 |
GO:0046634 | Stomach | CAG | regulation of alpha-beta T cell activation | 9/552 | 104/18723 | 3.62e-03 | 3.38e-02 | 9 |
GO:0031349 | Stomach | CAG | positive regulation of defense response | 17/552 | 278/18723 | 3.81e-03 | 3.52e-02 | 17 |
GO:003133131 | Stomach | CAG | positive regulation of cellular catabolic process | 23/552 | 427/18723 | 4.22e-03 | 3.82e-02 | 23 |
GO:19035572 | Stomach | CAG | positive regulation of tumor necrosis factor superfamily cytokine production | 9/552 | 107/18723 | 4.38e-03 | 3.92e-02 | 9 |
GO:0034145 | Stomach | CAG | positive regulation of toll-like receptor 4 signaling pathway | 3/552 | 12/18723 | 4.60e-03 | 4.05e-02 | 3 |
GO:00326123 | Stomach | CAG | interleukin-1 production | 10/552 | 128/18723 | 4.64e-03 | 4.06e-02 | 10 |
GO:00326523 | Stomach | CAG | regulation of interleukin-1 production | 10/552 | 128/18723 | 4.64e-03 | 4.06e-02 | 10 |
GO:00506783 | Stomach | CAG | regulation of epithelial cell proliferation | 21/552 | 381/18723 | 4.71e-03 | 4.12e-02 | 21 |
GO:00421293 | Stomach | CAG | regulation of T cell proliferation | 12/552 | 171/18723 | 4.85e-03 | 4.22e-02 | 12 |
GO:00706653 | Stomach | CAG | positive regulation of leukocyte proliferation | 11/552 | 150/18723 | 4.95e-03 | 4.25e-02 | 11 |
GO:0002697 | Stomach | CAG | regulation of immune effector process | 19/552 | 339/18723 | 5.87e-03 | 4.75e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMGB1 | SNV | Missense_Mutation | | c.120N>C | p.Glu40Asp | p.E40D | P09429 | protein_coding | deleterious(0.02) | benign(0.105) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
HMGB1 | SNV | Missense_Mutation | | c.131A>C | p.Lys44Thr | p.K44T | P09429 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.624A>T | p.Glu208Asp | p.E208D | P09429 | protein_coding | tolerated_low_confidence(0.26) | benign(0) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.443C>G | p.Ala148Gly | p.A148G | P09429 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HMGB1 | SNV | Missense_Mutation | novel | c.377C>T | p.Ala126Val | p.A126V | P09429 | protein_coding | deleterious(0.03) | benign(0.221) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.168G>T | p.Glu56Asp | p.E56D | P09429 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
HMGB1 | SNV | Missense_Mutation | | c.253N>G | p.Thr85Ala | p.T85A | P09429 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.23N>G | p.Lys8Arg | p.K8R | P09429 | protein_coding | deleterious(0.02) | benign(0.358) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.25N>T | p.Pro9Ser | p.P9S | P09429 | protein_coding | deleterious(0.04) | possibly_damaging(0.573) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.488G>A | p.Arg163Gln | p.R163Q | P09429 | protein_coding | tolerated(0.16) | benign(0.193) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | PREDNISOLONE | PREDNISOLONE | 18447956 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AUTOLOGOUS DENDRITIC CELLS | | 16997859 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | ADJUVANT | | 15161015 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | SALINE | SODIUM CHLORIDE | 17334244 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | DISTAMYCIN | | 9161031 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | GP100 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | CHLORAMPHENICOL | CHLORAMPHENICOL | 9931456 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | EGCG | EPIGALOCATECHIN GALLATE | 17987129 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | MART1 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AMPICILLIN | AMPICILLIN | 9931456 |